Calcilytix Therapeutics, Inc. Report issue

For profit Phase 2
Founded: San Francisco CA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04581629
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Calcilytix Therapeutics, Inc. | Calcilytix Therapeutics, Inc., a BridgeBio company

Active Ingredients

Drugs in Phase 2 Trials (1)

encaleret (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthrogryposis (Phase 2)

Hypocalcemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1